Trials / Unknown
UnknownNCT04619329
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm): A Single Center, Open, Randomized Controlled Trial.
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Beijing Tsinghua Chang Gung Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | GSMs-TACE | TACE using Lobaplatin (30-40mg/m2) and gelatin sponge microspheres (150-350μm, 350-560μm, 560-710μm or 710-1000μm) |
| PROCEDURE | Surgical Resection | Surgical Resection of HCC |
Timeline
- Start date
- 2020-10-30
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
- First posted
- 2020-11-06
- Last updated
- 2020-11-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04619329. Inclusion in this directory is not an endorsement.